Gujarat Themis Biosyn Ltd (GUJTHEM) is currently trading at 428.45 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Gujarat Themis Biosyn Limited is a Vapi-based pharmaceutical company specialized in fermentation‑based intermediates and APIs, historically known for rifamycin intermediates and recently commissioned a multi-purpose API plant to forward‑integrate its value chain and target domestic and export markets. The company reported Q3 FY26 revenue of Rs. 43.37 crore (up ~9.7% YoY) with an exceptionally high EBITDA margin of 49.1% in the quarter, reflecting tight cost optimization and volume growth despite higher manpower and depreciation costs during capex ramp-up. GTBL has completed significant capex: a new fermentation facility and a commercial API unit (operations from 6 May 2025), and its balance sheet shows PPE rising sharply and non‑current borrowings increasing, underlining an active investment phase to expand capacity and product mix. Management disclosed R&D spend of about 3% of revenue for the nine months, ongoing validation batches for API blocks, and is establishing a new R&D center; the company targets forward integration and export expansion while also commissioning an 18.5 MW captive wind‑solar hybrid plant to reduce power costs and carbon footprint.

Over the past 52 weeks, Gujarat Themis Biosyn Ltd has traded between a low of ₹225.75 and a high of ₹479.45. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Gujarat Themis Biosyn Ltd has a market capitalization of approximately 5,509.97. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Gujarat Themis Biosyn Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 113.19 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 5,509.97 Cr, Gujarat Themis Biosyn Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Gujarat Themis Biosyn Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Gujarat Themis Biosyn Ltd is 113.19. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

The board approved a preferential allotment of 82.11 lakh equity shares at ₹408 per share, aggregating to ₹335 crore, subject to shareholder and stock exchange approvals.

The company fixed the QIP issue price at ₹354 per equity share, including a premium of ₹353 per share over the ₹1 face value.

The QIP issue price was fixed at ₹354 per equity share, as approved on August 28, 2026.

The QIP was closed at an issue price of ₹354 per equity share, as approved by the Fund-Raising Committee on August 28, 2026.